Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
linear decrease » linear increase (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
linear decrease » linear increase (Expand Search)
-
2241
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2242
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2243
-
2244
-
2245
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2246
-
2247
-
2248
-
2249
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2250
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2251
-
2252
-
2253
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2254
-
2255
-
2256
-
2257
-
2258
-
2259
-
2260